[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2015005762A - Producto de comicronizacion que comprende acetato de ulipristal. - Google Patents

Producto de comicronizacion que comprende acetato de ulipristal.

Info

Publication number
MX2015005762A
MX2015005762A MX2015005762A MX2015005762A MX2015005762A MX 2015005762 A MX2015005762 A MX 2015005762A MX 2015005762 A MX2015005762 A MX 2015005762A MX 2015005762 A MX2015005762 A MX 2015005762A MX 2015005762 A MX2015005762 A MX 2015005762A
Authority
MX
Mexico
Prior art keywords
ulipristal acetate
micronisation
product
micronisation product
relates
Prior art date
Application number
MX2015005762A
Other languages
English (en)
Other versions
MX363699B (es
Inventor
Florian Battung
Pierre-Yves Juvin
Jérôme Hecq
Aude Colin
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of MX2015005762A publication Critical patent/MX2015005762A/es
Publication of MX363699B publication Critical patent/MX363699B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Circuit Arrangements For Discharge Lamps (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Thyristors (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención tiene por objeto un producto de comicronización que comprende una sustancia activa elegida entre el grupo constituido por el acetato de ulipristal, un metabolito del acetato de ulipristal y sus mezclas, y un tensioactivo sólido aceptable desde el punto de vista farmacéutico. La invención se refiere también a una composición farmacéutica que comprende dicho producto de comicronización y sus utilizaciones terapéuticas.
MX2015005762A 2012-11-08 2013-11-07 Producto de comicronizacion que comprende acetato de ulipristal. MX363699B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1260603A FR2997627B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant de l'ulipristal acetate
PCT/FR2013/052670 WO2014072646A1 (fr) 2012-11-08 2013-11-07 Produit de co-micronisation comprenant de l'ulipristal acetate

Publications (2)

Publication Number Publication Date
MX2015005762A true MX2015005762A (es) 2016-02-11
MX363699B MX363699B (es) 2019-03-28

Family

ID=47878175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005762A MX363699B (es) 2012-11-08 2013-11-07 Producto de comicronizacion que comprende acetato de ulipristal.

Country Status (30)

Country Link
US (2) US9610293B2 (es)
EP (1) EP2916871B1 (es)
JP (1) JP2015536968A (es)
KR (1) KR20150093170A (es)
CN (1) CN104902928B (es)
AR (1) AR093402A1 (es)
AU (1) AU2013343320B2 (es)
BR (1) BR112015010271B1 (es)
CA (1) CA2890272A1 (es)
CR (1) CR20150297A (es)
CY (1) CY1119542T1 (es)
DK (1) DK2916871T3 (es)
EA (1) EA027641B1 (es)
EC (1) ECSP15022442A (es)
ES (1) ES2606307T3 (es)
FR (1) FR2997627B1 (es)
GE (1) GEP201706637B (es)
HR (1) HRP20161624T1 (es)
HU (1) HUE031911T2 (es)
LT (1) LT2916871T (es)
MD (1) MD4563C1 (es)
MX (1) MX363699B (es)
PL (1) PL2916871T3 (es)
PT (1) PT2916871T (es)
RS (1) RS55429B1 (es)
SI (1) SI2916871T1 (es)
SM (1) SMT201600445B (es)
TW (1) TWI617325B (es)
UA (1) UA117465C2 (es)
WO (1) WO2014072646A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
CN103923154B (zh) * 2013-01-16 2017-09-26 杭州容立医药科技有限公司 醋酸乌利司他的共晶及制备方法
CN105663140A (zh) * 2014-11-21 2016-06-15 四川海思科制药有限公司 一种含醋酸乌利司他的药物组合物及其制备方法
CN104865215A (zh) * 2015-05-16 2015-08-26 南京海纳医药科技有限公司 一种醋酸乌利司他片剂及其溶出度测定方法
CN105919150A (zh) * 2016-05-12 2016-09-07 高洁珺 一种代替压片工艺中化工添加剂的方法
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US8865200B2 (en) 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
WO2008037044A1 (en) 2006-09-27 2008-04-03 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
AU2007338843B2 (en) 2006-12-20 2013-05-09 Teva Women's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
KR20090086470A (ko) * 2006-12-28 2009-08-12 레프로스 쎄라피우틱스 아이엔씨. 앤티프로게스틴의 개선된 생물학적 이용가능성을 위한 방법들과 제형들
WO2009067557A1 (en) * 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
NZ595790A (en) 2009-04-14 2013-11-29 Hra Pharma Lab Method for on-demand contraception
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate

Also Published As

Publication number Publication date
UA117465C2 (uk) 2018-08-10
CN104902928A (zh) 2015-09-09
EP2916871B1 (fr) 2016-09-14
EP2916871A1 (fr) 2015-09-16
CA2890272A1 (fr) 2014-05-15
ECSP15022442A (es) 2016-01-29
US20150290218A1 (en) 2015-10-15
PT2916871T (pt) 2016-12-15
BR112015010271A2 (pt) 2017-07-11
AU2013343320B2 (en) 2018-03-08
EA027641B1 (ru) 2017-08-31
HRP20161624T1 (hr) 2017-01-27
MD4563B1 (ro) 2018-05-31
US20170157146A1 (en) 2017-06-08
WO2014072646A1 (fr) 2014-05-15
BR112015010271B1 (pt) 2020-04-22
MD20150053A2 (ro) 2015-10-31
FR2997627A1 (fr) 2014-05-09
AR093402A1 (es) 2015-06-03
CY1119542T1 (el) 2018-03-07
MD4563C1 (ro) 2018-12-31
SMT201600445B (it) 2017-01-10
US9610293B2 (en) 2017-04-04
MX363699B (es) 2019-03-28
TWI617325B (zh) 2018-03-11
ES2606307T3 (es) 2017-03-23
JP2015536968A (ja) 2015-12-24
CN104902928B (zh) 2018-10-23
PL2916871T3 (pl) 2017-02-28
DK2916871T3 (da) 2017-01-02
FR2997627B1 (fr) 2015-01-16
RS55429B1 (sr) 2017-04-28
BR112015010271A8 (pt) 2019-10-01
LT2916871T (lt) 2016-12-27
GEP201706637B (en) 2017-03-10
CR20150297A (es) 2015-08-14
TW201427718A (zh) 2014-07-16
SI2916871T1 (sl) 2017-03-31
AU2013343320A1 (en) 2015-06-04
KR20150093170A (ko) 2015-08-17
EA201500513A1 (ru) 2015-08-31
HUE031911T2 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MY163083A (en) Solid forms of a pharmaceutically active substance
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
MX348823B (es) Formulaciones estables de linaclotida.
WO2012174158A3 (en) Administration of benzodiazepine
MX359288B (es) Forma iv del clorhidrato de ivabradina.
IN2015DN03984A (es)
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
AU2012347200A8 (en) Tablet capable of combatting misuse by injection
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
WO2014121764A3 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
IN2015DN02296A (es)
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2014DN07897A (es)
PL2678006T3 (pl) Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents